Actionable Results
A targeted set of 17 genes and 59 exons that are key in diagnosis, prognosis, and approved therapeutic options in solid adult tumors.
Gene fusions are the result of other genomic events, such as translocation, interstitial deletion, or chromosomal inversion. Gene fusions are known to be driver mutations in many different tumors and more recently, have emerged as therapeutic targets.
While relatively rare, for example ALK rearrangements have been reported as occurring in only 3–8% of non-small lung cell cases, the emergence of targeted gene fusion therapies have made the assessment of these events in tumors extremely important.
While single gene testing methods remain the standard, multigene NGS assays provide an alternative single assay approach to gene fusion detection that conserves often difficult to obtain tissue samples.
Detect known and novel fusions with Fusions, a partner-agnostic FFPE RNA-based multiplex amplicon assay.
Imagia Canexia Health’s Fusions panel is designed to target a set of 17 genes and 59 exons that are key in diagnosis, prognosis, and approved therapeutic options in solid adult tumors.
Gene | Exon |
---|---|
ALK | 2, 10, 16-22 |
BRAF | 2, 6-12,15,19 |
CSF1 | 6-8 |
EGFR | 1-3, 7-9,11, 13,16, 20-21, 24-25, 27, 8, 23 |
ERG | 2-11 |
FGFR1 | 1-10, 14,17 |
FGFR2 | 2, 8-10,13, 16-17 |
FGFR3 | 2-4, 8-10, 16-18 |
MET | 2-6, 13-17, 21 |
NRG1 | 1, 1-8 |
NTRK1 | 2, 7-13 |
NTRK2 | 10-17 |
NTRK3 | 7, 12-18 |
PDGFB | 2 |
PPARG | 2, 7 |
RAF1 | 2, 8-10 |
RET | 2-4, 7-13 |
ROS1 | 31-37 |
Genes | 18 |
---|---|
Exons | 150 |
Turnaround time | 3 to 5 days |
Sensitivity | 95% |
Specificity | 100% |
Reproducibility | 100% (same input replicates), 91.67% (including replicates with different input |
A targeted set of 17 genes and 59 exons that are key in diagnosis, prognosis, and approved therapeutic options in solid adult tumors.
A simple laboratory workflow that provides rapid, reliable, results.
Review detailed interpretations, current treatment options, and available clinical trials.
Targeted amplicon-based technology provides an economical alternative to single-gene testing or hybrid capture NGS assays.
Imagia Canexia Health Fusions assay allows for simultaneous hotspot testing, reducing the amount of biopsy tissue required, when compared to single-gene testing.
All Imagia Canexia Health assays and software are developed in our CLIA, CAP, CDPH and DAP accredited laboratory.
Imagia Canexia Health’s Follow It panel detects mutations in plasma. Plasma profiling (a type of liquid biopsy) can be used to help tailor treatment, monitor cancer progression, or detect treatment resistance.
Imagia Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.
Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help make more informed treatment decisions.
Perform world-leading mutation assays, right from your laboratory: Imagia Canexia Health’s proprietary bioinformatics platform covers everything from mutation identification to auto-generated clinical reports.
Imagia Canexia Health’s expert and cost-effective assays, informatics, and support mean rapid assay results. Learn how partnering with Imagia Canexia can help you bring precision oncology in-house.